Extended Data Fig. 2: Metabolic and histone changes following safusidenib treatment.
From: Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial
a. Longitudinal concentration (ng/mL) of safusidenib in the plasma over the four post-safusidenib study timepoints: days 1, 8, post 15, 28, and day of surgery (± 2 days) (n = 10 matched longitudinal samples). b. Correlation of percent change in 2-HG with participant tumor safusidenib concentration (n = 10 participants). c. 2-hydroxyglutarate (2-HG) quantification (µM) by LC-MS in tissue, CSF and plasma at the pre- and post-safusidenib timepoints (n = 10 matched samples). d. 2-HG quantification (µM) by GC-MS in tissue, CSF and plasma at the pre- and post-safusidenib timepoints (n = 10 participants). e. Spatial metabolomics examining 2-HG (m/z: 209.10 adducts: M+IsoProp+H) in participant A-05. Detected intensity score, above, 3D density map extrapolated from intensity, below. Scale, 1 mm. f. Heatmap of the top altered metabolites in each sample. g. Specific histone marks altered pre- and post-safusidenib (n = 8 participants). Box indicates IQR, centre line is median; whiskers extend to the furthest points within 1.5 × IQR.
